Latest news with #Bondholders
Yahoo
2 hours ago
- Business
- Yahoo
Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204* million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350) and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079) (the Repurchase Offer) launched on June 25, 2025. As of the end of the main offer period, Bondholders have accepted the Repurchase Offer for the CB 2025 with an aggregate nominal value of CHF 185'388'000, corresponding to 90.88% of the total issued nominal value of the CB 2025, and for the CB 2028 with an aggregate nominal value of CHF 561'800'000, corresponding to 93.63% of the total issued nominal value of the CB 2028, well exceeding the minimum acceptance rate of 85% each. An additional acceptance period of five trading days for the subsequent acceptance of the Repurchase Offer will begin on August 12, 2025, and end at 17:30 CEST on August 18, 2025. The settlement of the Repurchase Offer is currently expected to take place on or about August 26, 2025, subject to the satisfaction or waiver of certain offer conditions. The notice of the interim results and all other documentation in relation to the Repurchase Offer (the Repurchase Offer Documentation) can be found at the following link: * The total nominal value of the CB 2025 was increased from CHF 200,000,000 to CHF 204,000,000 as of July 17, 2025. Notes to the editor and legal notes About IdorsiaThe purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 – – Legal Notice and InformationThe above information contains or may contain certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. The information contained in this media release is for information purposes only and does not constitute, or form part of, an offer or invitation to purchase, sell, exchange or issue, or a solicitation of an offer to sell, purchase, exchange or subscribe to, any securities of Idorsia Ltd or Idorsia Investments SARL, including without limitation the CB 2025 and the CB 2028, or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract therefor. This media release is not part of the Repurchase Offer Documentation in relation to the Repurchase Offer. Terms and conditions of the Repurchase Offer have been and/or will be published in the Repurchase Offer Documentation. Holders of CB 2025 and/or CB 2028 are urged to read the Repurchase Offer Documentation, which is and/or will be available at This media release is not a financial product or investment advice, nor is it a recommendation to acquire, exchange or dispose of securities or accounting, legal or tax advice. It has been prepared without taking into account the objectives, legal, financial or tax situation and needs of individuals. Before making any investment decision, individuals should read the Repurchase Offer Documentation and consider the appropriateness of the information having regard to their own objectives, legal, financial and tax situation and needs and seek legal, tax and other advice as appropriate for their individual needs and jurisdiction. Offer RestrictionsThis media release is only intended for distribution to non-U.S. persons (within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended). This media release is not an offer to tender securities or an offer of securities. The Repurchase Offer is being made on the basis of the Repurchase Offer Documentation only and is subject to the restrictions described therein. The Repurchase Offer is not being made, and will not be made, directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. Attachment Press Release PDFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
10-07-2025
- Business
- Wall Street Journal
Venezuela's Disputed Bond Complicates Citgo Sale
Bondholders are moving to block the forced sale of Venezuela's Citgo Petroleum, setting up a clash with some of the country's other creditors over control of its most valuable external asset. A group of bondholders owed some $1.7 billion by Citgo's ultimate parent company, Petróleos de Venezuela SA, has been excluded from the latest offer for the company. The group, referred to as the 2020 bondholders, had agreed to a deal in April with Citgo's previous leading bidder, Contrarian Capital-backed Red Tree Investments.
Yahoo
24-06-2025
- Business
- Yahoo
SPIE - NOTICE OF REDEMPTION - Bonds due June 18, 2026
NOTICE OF REDEMPTION TERMSTO HOLDERS OF SPIE(the 'Issuer')€600,000,000 2.625 per cent. Bonds due June 18, 2026 (the 'Bonds') ISIN: FR0013426376Common Code: 201374006 Optional Make Whole Redemption Date: June 27, 2025Optional Redemption Amount: €100,526.35 per €100,000 Bond Cergy, June 24, 2025 - Following the publication by the Issuer on May 28, 2025 of a notice announcing that it has elected to redeem all of the outstanding Bonds (of which €600,000,000 are currently outstanding) on June 27, 2025 (the 'Make-whole Redemption Date') at a price per €100,000 Bond equal to the Optional Redemption Amount, pursuant to Conditions 6.4.2 (Make Whole Redemption by the Issuer) and 11 (Notices) of the terms and conditions of the Bonds contained in the prospectus relating to the issue of the Bonds which received visa no. 19-268 of the French Autorité des marchés financiers on June 14, 2019 (the 'Prospectus'), notice is hereby given to the Bondholders of the terms of the upcoming redemption: 1. The Optional Redemption Amount has been calculated by the Calculation Agent in accordance with the provisions of Condition 6.4.2 of the Prospectus. In accordance with such Condition, the Optional Redemption Amount is computed using a discount rate equal to the relevant Early Redemption Rate (determined as of 11:00 a.m. (Central European time (CET)) on June 23, 2025) plus an Early Redemption Margin of 0.30 per cent. and plus interest accrued on the Bonds to, but excluding the Optional Make Whole Redemption Date, all as determined by the Calculation Agent. 2. The Early Redemption Rate is 1.8410%. 3. Interest accrued to, but excluding, the Optional Make Whole Redemption Date is €64.73 per €100,000 Bond. 4. The Optional Redemption Amount is €100,526.35 per €100,000 Bond. The Bonds will be delisted from Euronext Paris on the Optional Make Whole Redemption Date. Terms used but not defined herein shall have the meanings ascribed to them in the Prospectus. Attachment SPIE - NOTICE OF REDEMPTION - Bonds due June 18, 2026Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
13-05-2025
- Business
- Reuters
New Fortress Energy pushes quarterly report filing due to delay in Jamaica business sale
May 13 (Reuters) - U.S.-based LNG company New Fortress Energy (NFE.O), opens new tab said on Tuesday it would push its quarterly filing with the U.S. securities regulator due to delay in completing the previously announced sale of its business in Jamaica. In March, Excelerate Energy agreed to buy New Fortress Energy's Jamaica business for $1.06 billion in cash, with the transaction expected to close in the near term. The company began exploring various options last year, which included bringing in strategic partners or selling assets, after it was forced to defer shareholder dividend payments while negotiating with bondholders to address near-term debt maturities. New Fortress added that the extension was partly a result of the resignation of its accounting chief, effective April 29, which diverted time and resources from the routine preparation and review of quarterly reports.
